{"component": "definition", "props": {"groups": [{"size": 6, "snippet": "means the Network has succeeded in registering one million Verified Users.", "snippet_links": [{"key": "the-network", "type": "definition", "offset": [6, 17]}], "samples": [{"hash": "7BuZFP8xlkP", "uri": "/contracts/7BuZFP8xlkP#second-milestone", "label": "Limited Partnership Agreement (Blockstack Inc.)", "score": 30.5140323639, "published": true}, {"hash": "63Cbc1Egvg6", "uri": "/contracts/63Cbc1Egvg6#second-milestone", "label": "Limited Partnership Agreement (Blockstack Inc.)", "score": 30.5140323639, "published": true}, {"hash": "3A52NeGwPSx", "uri": "/contracts/3A52NeGwPSx#second-milestone", "label": "Limited Partnership Agreement (Blockstack Inc.)", "score": 30.5140323639, "published": true}], "hash": "b42920fe13524f8546a02831193b5da9", "id": 1}, {"size": 5, "snippet": "has the meaning set forth in Section 1.3(a).", "snippet_links": [], "samples": [{"hash": "bCtBnHWh8eH", "uri": "/contracts/bCtBnHWh8eH#second-milestone", "label": "Purchase and Sale Agreement (Galera Therapeutics, Inc.)", "score": 30.7741279602, "published": true}, {"hash": "lsmYQLURqGp", "uri": "/contracts/lsmYQLURqGp#second-milestone", "label": "Purchase and Sale Agreement (Galera Therapeutics, Inc.)", "score": 30.3059539795, "published": true}, {"hash": "bM1XihSid9E", "uri": "/contracts/bM1XihSid9E#second-milestone", "label": "Purchase and Sale Agreement", "score": 26.1704311371, "published": true}], "hash": "328f873fa8a43b566d65067a8b6c2f5e", "id": 2}, {"size": 3, "snippet": "means completion of recruitment for the clinical studies, i.e., completion of all of the surgeries on all of the patients recruited for both total cervical disc replacement and control fusion, in accordance with an IDE approved by the FDA initiated by Buyer or any of its Affiliates or licensees.", "snippet_links": [{"key": "completion-of", "type": "definition", "offset": [6, 19]}, {"key": "clinical-studies", "type": "definition", "offset": [40, 56]}, {"key": "in-accordance-with", "type": "definition", "offset": [193, 211]}, {"key": "approved-by", "type": "definition", "offset": [219, 230]}, {"key": "the-fda", "type": "clause", "offset": [231, 238]}, {"key": "by-buyer", "type": "clause", "offset": [249, 257]}], "samples": [{"hash": "ji3x9aebOcd", "uri": "/contracts/ji3x9aebOcd#second-milestone", "label": "Asset Purchase Agreement", "score": 31.3408622742, "published": true}, {"hash": "2bGklCBDVpY", "uri": "/contracts/2bGklCBDVpY#second-milestone", "label": "Asset Purchase Agreement (Nuvasive Inc)", "score": 21.0, "published": true}, {"hash": "7QRrAeqZrlu", "uri": "https://ir.nuvasive.com/static-files/e3c5d4d5-3b7a-4193-88c1-96ab2eadcfd6", "label": "ir.nuvasive.com", "score": 8.7316904068, "published": false}], "hash": "550a5ade26eb6bc92a00c86a28eac115", "id": 3}, {"size": 3, "snippet": ", Third Milestone\", \"Fourth Milestone\", \"Fifth Milestone\", and \"Sixth Milestone\", respectively.", "snippet_links": [{"key": "third-milestone", "type": "definition", "offset": [2, 17]}, {"key": "fourth-milestone", "type": "definition", "offset": [21, 37]}, {"key": "fifth-milestone", "type": "definition", "offset": [41, 56]}], "samples": [{"hash": "fC6zFmG5r7L", "uri": "/contracts/fC6zFmG5r7L#second-milestone", "label": "Option Agreement (B Twelve Inc)", "score": 18.0, "published": true}, {"hash": "93244Mi2d7F", "uri": "/contracts/93244Mi2d7F#second-milestone", "label": "Option Agreement (B Twelve Inc)", "score": 18.0, "published": true}], "hash": "e2d25af32d03c8e6115b548f6a7e3ebc", "id": 4}, {"size": 3, "snippet": "has the meaning set forth in Section 2.6(b)(ii).", "snippet_links": [], "samples": [{"hash": "39SnikobqzV", "uri": "/contracts/39SnikobqzV#second-milestone", "label": "Asset Purchase Agreement (Nabi  Biopharmaceuticals)", "score": 21.0, "published": true}], "hash": "d9cb6d9482145a339a233f22561805ed", "id": 5}, {"size": 3, "snippet": "means \u201c***\u201d", "snippet_links": [], "samples": [{"hash": "dHWGiiJa78r", "uri": "/contracts/dHWGiiJa78r#second-milestone", "label": "Asset Purchase Agreement (Cambridge Display Technology, Inc.)", "score": 21.0, "published": true}], "hash": "28e8bdfb32d663c85cdd31a7c1ad9674", "id": 6}, {"size": 2, "snippet": "is as follows: \u00b7 The dosing of the first patient in the first clinical trial for a product candidate where: (i) the United States Food and Drug Administration (or any foreign equivalent administrative body unless determined by the Company\u2019s Board of Directors not to be acceptable for this purpose) would recognize such clinical trial, assuming successful completion, as a pivotal study for submission of a New Drug Application or a Biologics License Application (or any foreign equivalent application) for the product candidate as determined in the reasonable discretion of the Company\u2019s Board of Directors, although any Phase III clinical study (as defined in 21 C.F.R. \u00a7312.21(c)) will be presumed to satisfy this requirement; and (ii) such product candidate is covered by any intellectual property right held (whether owned, co-owned, licensed or otherwise controlled) by the Company.", "snippet_links": [{"key": "first-patient-in", "type": "definition", "offset": [35, 51]}, {"key": "first-clinical-trial", "type": "definition", "offset": [56, 76]}, {"key": "product-candidate", "type": "definition", "offset": [83, 100]}, {"key": "the-united-states", "type": "definition", "offset": [112, 129]}, {"key": "food-and-drug-administration", "type": "definition", "offset": [130, 158]}, {"key": "foreign-equivalent", "type": "definition", "offset": [167, 185]}, {"key": "administrative-body", "type": "definition", "offset": [186, 205]}, {"key": "by-the-company", "type": "clause", "offset": [224, 238]}, {"key": "board-of-directors", "type": "definition", "offset": [241, 259]}, {"key": "successful-completion", "type": "clause", "offset": [345, 366]}, {"key": "pivotal-study", "type": "definition", "offset": [373, 386]}, {"key": "submission-of", "type": "clause", "offset": [391, 404]}, {"key": "new-drug-application", "type": "definition", "offset": [407, 427]}, {"key": "biologics-license-application", "type": "clause", "offset": [433, 462]}, {"key": "the-product", "type": "definition", "offset": [507, 518]}, {"key": "discretion-of-the-company", "type": "clause", "offset": [561, 586]}, {"key": "phase-iii-clinical-study", "type": "definition", "offset": [622, 646]}, {"key": "covered-by", "type": "definition", "offset": [765, 775]}, {"key": "intellectual-property-right", "type": "definition", "offset": [780, 807]}], "samples": [{"hash": "k9qC45GfLTK", "uri": "/contracts/k9qC45GfLTK#second-milestone", "label": "Restricted Stock Issuance Agreement (Receptos, Inc.)", "score": 24.2553043365, "published": true}, {"hash": "4GlUltjg31S", "uri": "/contracts/4GlUltjg31S#second-milestone", "label": "Restricted Stock Issuance Agreement (Receptos, Inc.)", "score": 24.1184120178, "published": true}], "hash": "5e224486d5fc2c5c5dc5ea979a5864a5", "id": 7}, {"size": 2, "snippet": "means the milestone set forth on Annex A under the heading \u201cSecond Milestone.\u201d \u201cSecond Milestone Payment\u201d has the meaning set forth in Annex A.", "snippet_links": [{"key": "annex-a", "type": "definition", "offset": [33, 40]}, {"key": "second-milestone-payment", "type": "definition", "offset": [80, 104]}], "samples": [{"hash": "ewVXxNAc5SC", "uri": "https://investors.abeonatherapeutics.com/all-sec-filings/content/0001144204-15-049914/0001144204-15-049914.pdf", "label": "investors.abeonatherapeutics.com", "score": 9.1273097992, "published": false}, {"hash": "2mX69Bn9klF", "uri": "https://investors.abeonatherapeutics.com/all-sec-filings/content/0001144204-15-049282/0001144204-15-049282.pdf", "label": "investors.abeonatherapeutics.com", "score": 9.1273097992, "published": false}], "hash": "e275c139af59218a438fcd3d3befe5bd", "id": 8}, {"size": 2, "snippet": "means the earlier of: (a) completion of a Feasibility Study, and (b) five (5) years from the Closing Date.", "snippet_links": [{"key": "completion-of-a", "type": "clause", "offset": [26, 41]}, {"key": "feasibility-study", "type": "definition", "offset": [42, 59]}, {"key": "the-closing-date", "type": "clause", "offset": [89, 105]}], "samples": [{"hash": "e3FaZMPdJIw", "uri": "/contracts/e3FaZMPdJIw#second-milestone", "label": "Share Purchase Agreement (Novagold Resources Inc)", "score": 29.5831623077, "published": true}, {"hash": "74XB4WQd2vd", "uri": "/contracts/74XB4WQd2vd#second-milestone", "label": "Share Purchase Agreement (Novagold Resources Inc)", "score": 28.7529087067, "published": true}], "hash": "2361abfa6a9a9c8c73d79662ccb67de8", "id": 9}, {"size": 2, "snippet": "means the milestone set forth on Annex A under the heading \u201cSecond Milestone.\u201d", "snippet_links": [{"key": "annex-a", "type": "definition", "offset": [33, 40]}], "samples": [{"hash": "gP2ob5pQ0qS", "uri": "/contracts/gP2ob5pQ0qS#second-milestone", "label": "Merger Agreement (Abeona Therapeutics Inc.)", "score": 26.6153316498, "published": true}, {"hash": "f1bicASleme", "uri": "/contracts/f1bicASleme#second-milestone", "label": "Merger Agreement (Abeona Therapeutics Inc.)", "score": 26.6153316498, "published": true}], "hash": "f7f6771f7eefdc50245adda9ffa5a928", "id": 10}], "next_curs": "Cl0SV2oVc35sYXdpbnNpZGVyY29udHJhY3RzcjkLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIZc2Vjb25kLW1pbGVzdG9uZSMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"title": "Second Milestone", "size": 98, "snippet": "means the Network has succeeded in registering one million Verified Users.", "id": "second-milestone", "examples": ["For the avoidance of doubt, each Milestone Payment Amount shall only be paid one time, if at all, subject to the achievement of the applicable Milestone prior to the earlier of Milestone Expiration and Termination, and the maximum aggregate potential amount payable under this Agreement per CVR shall be $1.00 with respect to the First Milestone, $0.50 with respect to the <strong>Second Milestone</strong>, and $1.00 with respect to the Third Milestone.", "With respect to a First CVR Product, Parent shall not be obligated to provide any report after the making of the Third Milestone Payment or after the Third Milestone Expiration, and with respect to a Second CVR Product, Parent shall not be obligated to provide any report after the making of the <strong>Second Milestone</strong> Payment or after the <strong>Second Milestone</strong> Expiration."], "related": [["milestone-2", "Milestone 2", "Milestone 2"], ["milestone-date", "Milestone Date", "Milestone Date"], ["milestone-1", "Milestone 1", "Milestone 1"], ["milestone", "Milestone", "Milestone"], ["development-milestone", "Development Milestone", "Development Milestone"]], "related_snippets": [], "updated": "2026-07-18T04:26:07+00:00"}, "json": true, "cursor": ""}}